Delving into the Latest Updates on Shanghai Yunyi Health Technology Development Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Antibody drug conjugate (ADC)

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	2
Monoclonal antibody	1

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	1
PD-1(Programmed cell death protein 1)	1
5T4(Trophoblast glycoprotein)	1

主要目的 1）评估PE0105单药治疗的安全性和耐受性； 2）确定PE0105单药治疗的最大耐受剂量（MTD）或最大给药剂量（MAD），以及II期试验推荐剂量（RP2D) 次要目的 1）分析PE0105在晚期实体肿瘤患者中单次给药的PK特性； 2）分析抗PE0105抗体（ADA）的产生情况； 3）按照RECIST1.1标准，初步评估PE0105在晚期实体肿瘤患者中的抗肿瘤活性。

[Translation]

Main objectives 1) Evaluate the safety and tolerability of PE0105 monotherapy; 2) Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of PE0105 monotherapy, as well as the recommended dose (RP2D) for Phase II trials Secondary objectives 1) Analyze the PK characteristics of a single dose of PE0105 in patients with advanced solid tumors; 2) Analyze the production of anti-PE0105 antibodies (ADA); 3) Preliminarily evaluate the anti-tumor activity of PE0105 in patients with advanced solid tumors according to RECIST1.1 criteria.

Start Date-

Sponsor / Collaborator

Shanghai Yunyi Health Technology Development Co., Ltd.

100 Clinical Results associated with Shanghai Yunyi Health Technology Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Yunyi Health Technology Development Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Shanghai Yunyi Health Technology Development Co., Ltd.

Huaxi Yaoxue Zazhi

Linear magnifying technology in preparative high performance liquid chromatography

Author: He, Meilian ; Cheng, Xiaowei

A review with 10 references on recent progress in the linear magnifying technol. of preparative HPLC.The essentials of the linear magnifying technol., factors affecting scale up in packing size, column dimension, and operating method were described.Perspective in the applications and development of preparative HPLC were discussed.

100 Deals associated with Shanghai Yunyi Health Technology Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yunyi Health Technology Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human anti-PD-1 monoclonal antibody(Shanghai Yunyi Health Technology Development Co Ltd) ( PD-1 )	Advanced Malignant Solid Neoplasm More	Phase 1
Anti-TPBG antibody-drug conjugate(XDCExplorer) ( 5T4 )	Neoplasms More	Preclinical
Anti-HER2 antibody-drug conjugate(XDCExplorer) ( HER2 )	Neoplasms More	Preclinical